This indication is approved under accelerated approval based on MRD response rate and hematological relapse-free survival (RFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
The accelerated approval is based on results from the Phase 2 single-arm BLAST study, which found that Blincyto converted most patients to an MRD-negative state after a single cycle of therapy.
Blincyto met the primary endpoint, inducing a complete MRD response, which is no detectable MRD, in 81% of patients. Median hematological RFS was 22.3 months.
Safety results among MRD-positive patients were consistent with the known safety profile of Blincyto in relapsed or refractory B-cell precursor ALL. The most common adverse reactions (greater than 20%) were pyrexia, infusion related reactions, headache, infections (pathogen unspecified), tremor and chills.
Blincyto is a bispecific CD19-directed CD3 T cell engager (BiTE) immunotherapy that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells. BiTE antibody constructs are a type of immunotherapy being investigated for fighting cancer by helping the body's immune system to detect and target malignant cells.
BiTE antibody constructs help place T cells within reach of the targeted cell, with the intent of causing T cells to inject toxins and trigger the cancer cell aptosis. BiTE antibody constructs are currently being investigated for their potential to treat a wide variety of cancers.
Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007